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COLORECTAL CANCER PATIENTS IN THE VETERAN POPULATION: A HEALTH
CARE COST AND UTILIZATION ANALYSIS IN THE UNITED STATES
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1STATinMED Research, Dallas, TX, USA, 2STATinMED Research/The University of Michigan,
Ann Arbor, MI, USA
OBJECTIVES:To assess the clinical and economic burden of colorectal cancer in the
US veteran population.METHODS: A retrospective study (October 01, 2005 to Sep-
tember 30, 2010) was conducted using the Veterans Health Affairs Medical SAS
Datasets. Patients diagnosed with colorectal cancer were included in the study.
Health care resource utilization and costswere assessed in the 12-month follow-up
period. Patients’ demographic, clinical and discharge statuses were compared us-
ing Chi-square testing and standardized differences. Student t-tests were used for
the means of continuous variables. Mortality and survival rates were calculated
using the Kaplan and Meier method and the PROC LIFETEST procedure. RESULTS:
In patients diagnosed with colorectal cancer (n92,494) in the total mortality rates
in the 12-month follow-up period were 33.11% (n28,716), with 52.72% for patients
age 39 and under, 25.53% for patients age 40 to 64, and 35.81% for patients age 65
and above. The most commonly ordered laboratory tests were sodium (4.12%),
potassium (4.07%), glucose quant (3.97%), chloride (3.93%) and creatinine (3.87%).
The average number of inpatient visits (0.58), emergency room (ER) (0.37), physician
office (28.55) and outpatient visits (28.89) were calculated for colorectal cancer
patients per patient, separately. We also calculated the percentage of inpatient
(29.33%), ER (17.86%), physician office (99.74%) and outpatient visits (99.78%). Pa-
tient expenditures for inpatient visits ($12,032), ER ($139), physician office ($8,728)
and outpatient visits ($9,005) were also computed. CONCLUSIONS: Based on cur-
rently available data, this analysis suggests that despite a standard mortality rate
increase with patient age, the highest mortality rate for colorectal cancer patients
in this population occurs among patients under age 40.
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ANALYSIS OF USING TRASTUZUMAB FOR THE TREATMENT OF ADVANCED
GASTRIC CANCER WITH HER2 POSITIVE
Lechuga D1, Gay JG2, Alva M1, Sanchez-kobayashi R2
1Roche Mexico, Mexico City, Mexico, 2TI Salud, Mexico City, Mexico
OBJECTIVES: To analyze which alternative treatment for advanced gastric cancer
with HER2 positive gives a better outcome in terms of life years gained (LY gained).
METHODS:An analysis of effectiveness using as outcomemeasure overall survival
by a Markov model with 3 stages: progression-free, progression and death, as al-
ternatives to taking trastuzumab plus chemotherapy (capecitabine/fluorouracil
and cisplatin), epirubicin  cisplatin  fluorouracil (ECF), cisplatin 
capecitabine  epirubicine (ECX), epirubicin  oxaliplatin  fluorouracil (EOF) and
epirubicin  oxaliplatin  capecitabine (EOX). The outcome was LY gained. The
effectiveness was obtained through survival curves of Kaplan-Meier overall sur-
vival for patients with advanced gastric cancer and overexpression of HER2 ob-
tained from ToGA (Bang et al 2010). The time horizon considered in the model was
8 years (96 months). This time horizon was also in the TA 208 evaluation appraisal
of trastuzumab as first-line treatment of the NICE. RESULTS: The treatment of
trastuzumab  chemotherapy proved more effectiveness than all other treatment
options. Trastuzumab generates 1.33 LY gained (life years) versus 1.04 of the che-
motherapies with capecitabine (ECX and EOX) and 0.92 of the chemotherapies with
fluorouracil (ECF and EOF) in HER2 positive patients. CONCLUSIONS: Trastuzumab
treatment for HER2 positive advanced gastric cancer proved to be the alternative
with more LY gained in comparison to all treatment options considered in this
study.
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IMPACT OF ANTICHOLINERGIC LOAD OF MEDICATIONS ON THE LENGTH OF
STAY OF CANCER PATIENTS IN HOSPICE CARE
Gupte KP, Wu WK
St. John’s University, Jamaica, NY, USA
OBJECTIVES: Anticholinergic medications are effective in the symptom control of
advanced cancer patients. However, use of these medications has been associated
with increased risk of side effects, which might lead to premature mortality. Ac-
cordingly, the study was conducted to examine the effect of increasing anticholin-
ergic load on the length of stay (LOS) of cancer patients in hospice care.METHODS:
2007 NHHCS was used as the data source. Cox Proportional Hazards Model was
used to investigate the risk of death among users of moderate and high anticho-
linergic load compared with users of low anticholinergic load in presence of other
prognostic factors. Patients whowere discharged alive andwhose discharge status
was unknown were censored. Data Analysis was performed using SAS version 9.1.
RESULTS: Of the 4109 patients receiving hospice care in 2007, 43.8% patients suf-
fered from a cancer diagnosis. Cancer patients (n  1801) on moderate anticholin-
ergic load had 12.7% lower hazard of death (p  0.0244) while those on high anti-
cholinergic load had 15.6% lower hazard of death (p 0.0071) as compared to those
patients on low anticholinergic load. Among other prognostic factors, non-elderly
age group (HR 1.33; p  0.0001), male gender (HR 1.17; p  0.0019), white race (HR
1.44; p  0.0005), metropolitan agency (HR 1.17; p  0.0039), non-profit agency (HR
1.23; p  0.0029), severe ADL dependency (HR 1.63; p  0.0001) and cognitive im-
pairment (HR 1.12; p  0.0358) were significantly associated with higher hazard of
death. CONCLUSIONS: The results suggest that increasing anticholinergic load
does not harm cancer patients using hospice care. The protective effect of increas-
ing anticholinergic load on the LOSmight be due to their clinical appropriateness in
the palliation of symptoms in advanced cancer patients. Future studies need to
evaluate the effect of increasing anticholinergic load on the quality-of-life of ad-
vanced cancer patients.
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INCIDENCE OF METASTATIC HORMONE RECEPTOR POSITIVE (HR) BREAST
CANCER IN THE UNITED KINGDOM (UK): DATA NEEDED!
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OBJECTIVES: In 2008, breast cancer accounted for 16% of cancer deaths in British
women. Although early stage breast cancer is treatable, prognosis for metastatic
breast cancer (mBC) cancer patients is poor. Information on incidence of HRmBC
in the UK is not readily available, as data on stage was not collected by cancer
registries until 2008. In this study,we estimate the incidence of HRmBC in theUK.
METHODS: Data reported by the International Agency for Research on Cancer was
used to estimate breast cancer incidence for 2008. Values were cross-checked with
Cancer Research UK.We then estimated the number of patients that were likely to
be HR and the number that were likely to progress to metastatic disease using
data from published literature and from the National Institute for Health and Clin-
ical Excellence. Surveillance, Epidemiology, and End Results data were used to
further cross-check values. RESULTS: It is estimated that of 46,458 incident breast
cancer patients per annum in the UK (89 per 100,000), 34,834 are HR (75%). Based
on 17 regional registries in the US, 1761 women were reported to be HR with
metastatic disease (63.5% of mBC cases) in 2008. Most literature-based values esti-
mate that up to 50% of breast cancer patients progress tometastatic disease. Based
on this assumption, among UK HR cases, an estimated 17,421 will likely progress
to metastatic disease (50% of HR cases or 37.5% of incident breast cancer cases).
CONCLUSIONS: There is a large gap in the literature on the incidence and preva-
lence rates of HR mBC in the UK. Our estimates revealed that most newly diag-
nosed breast cancer in the UK is HR, and about half will progress to metastatic
disease. The large number of HRmBC patients in the UK represents a significant
clinical and health care burden.
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EPIDEMIOLOGY OF THE NON-HODGKIN LYMPHOMA COLOMBIA 2000-2011
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OBJECTIVES: Review the Non-Hodgkin lymphoma (NHL) in the last 10 years and its
epidemiological behavior in Colombia.METHODS:We conducted a systematic re-
view of the literature on behavior and treatment of NHL (2000-2011), in PubMed,
EBSCO, Science Direct and Cochrane; employing combined MeSH terms with the
mean descriptor Non-Hodgkin Lymphoma. To determine the epidemiological be-
havior of the disease reviewed the Cancer Registry of Cali, deaths according to vital
statistics of DANE (ICD-10, C82-C85), GLOBOCAN records and Mortality Atlas Can-
cer in Colombia 2002-2006. RESULTS: In the period 2001-2005, the estimated inci-
dence rate for NHL was 10.5 in men and 7.8 women per 100,000 per-year. The
incidence rate is multiplied almost 10 times between 45 and 49 years old, until 25
times between 65 and 69 years and 30 times after 80 years of age. In 2000-2008, the
mortality rate was 1.87 per 100,000, it was: 2.11 in men and 1.63 in women per
100,000, for amale: female ratio of 1.26. Themedian age of the disease to Colombia
is 56 years. In 2006, the NHL was ranked eleventh in mortality in our country.
Among males was the tenth leading cause of death, and in women, the twelfth.
CONCLUSIONS: The NHL mortality rate in the period 2000-2008 shows a slight
upward trend, especially in the years 2005 and 2008. In Colombia, the increased risk
of death inmen compared to women, the distribution of deaths by age group, with
peaks in young adults (15-44 years) and seniors (65 years) - and the geographical
distribution has the highest mortality in the central region (area of industrial ac-
tivity) promote occupational scenarios. The treatment of NHL has advanced signif-
icantly in the last decade, with high mortality neoplasia became a curable type of
cancer in a high proportion of patients.
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EFFECT OF TREATMENTS FOR LATE-STAGE PROSTATE CANCER ON SURVIVAL
Ali AA, Xiao H, Adunlin GB
Florida A&M University, Tallahassee, FL, USA
OBJECTIVES:This study examined the relative effectiveness of treatments increas-
ing the survival time for late-stage prostate cancer. METHODS: Cox proportional
hazard regression model was used to assess overall survival in relation to various
treatments adjusting for confounding factors. Survival time was calculated from
the date of initial diagnosis to the last day of contact. Patient demographics, type of
health insurance stage, and grade of the tumor were extracted from Florida Cancer
Data System. Socioeconomic factorswere extracted fromCensus 2000. The types of
co-morbidity were formulated following the Elixhauser Index. The Census 2000
and Florida Agency for Health Care and Administration datasets were linked with
the Florida Cancer Data system for the time betweenOctober 1, 2001 andDecember
31, 2007 with survival being measured through October 31, 2008. RESULTS: A total
of 4336 men who had late-stage prostate cancer in Florida were analyzed. The
average age at the time of diagnosis was 65 and the average survival time was 253
days. Among patients who had late-stage prostate cancer, 59 percent received
surgical treatment only. The log-rank andWilcoxon tests indicated that therewere
significant differences in survival time by treatment options. The cox proportional
hazard regression result showed that patients who had received radiation only,
hormone only, and those who had chosen active surveillance were at a higher risk
of having shorter survival time than those who had received surgery only. The
existence of one or more co-morbidity, being diagnosed at an older age, and being
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